- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Biomarkers for Immunotherapy in Glioblastoma
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 8, Pages 1940
Publisher
MDPI AG
Online
2022-04-13
DOI
10.3390/cancers14081940
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword
- (2022) Sarah E. Blitz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapy for glioblastoma: the promise of combination strategies
- (2022) Mathilde Bausart et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
- (2022) Nourhan Abdelfattah et al. Nature Communications
- Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients
- (2022) Paola Del Bianco et al. Frontiers in Immunology
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
- (2022) Mathieu Seyfrid et al. Journal for ImmunoTherapy of Cancer
- Immunotherapeutic Approaches for Glioblastoma Treatment
- (2022) Nasser K. Yaghi et al. Biomedicines
- Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
- (2021) Matthias Gromeier et al. Nature Communications
- CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather
- (2021) Sarah M. Jacobs et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Combination immunotherapy strategies for glioblastoma
- (2021) Hok Yee Chan et al. JOURNAL OF NEURO-ONCOLOGY
- Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
- (2021) Jasneet Kaur Khalsa et al. Cells
- A vaccine targeting mutant IDH1 in newly diagnosed glioma
- (2021) Michael Platten et al. NATURE
- New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs
- (2021) Senthilnath Lakshmanachetty et al. Cells
- Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
- (2021) Marta Casarrubios et al. CLINICAL CANCER RESEARCH
- A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).
- (2021) Behnam Badie et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of glioblastoma immune subtypes and immune landscape based on a large cohort
- (2021) Huiyuan Zhang et al. HEREDITAS
- Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier
- (2021) Barrett D. Allen et al. FREE RADICAL BIOLOGY AND MEDICINE
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA
- (2021) Kristen Batich et al. NEURO-ONCOLOGY
- CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
- (2021) Michael Weller et al. NEURO-ONCOLOGY
- Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy
- (2021) Sara Magri et al. Cancers
- Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma
- (2021) Damla Isci et al. Cancers
- GD2 CAR T cells against human glioblastoma
- (2021) Malvina Prapa et al. npj Precision Oncology
- Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
- (2020) David A. Reardon et al. CLINICAL CANCER RESEARCH
- Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
- (2020) Dongrui Wang et al. Science Translational Medicine
- Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
- (2020) Katrin Aslan et al. Nature Communications
- Tumor-Specific T Cell Activation in Malignant Brain Tumors
- (2020) Malte Mohme et al. Frontiers in Immunology
- A review of glioblastoma immunotherapy
- (2020) Ravi Medikonda et al. JOURNAL OF NEURO-ONCOLOGY
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner
- (2020) Defne Bayik et al. Cancer Discovery
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?
- (2020) Paulo Linhares et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
- (2020) Phuong Nguyen et al. Molecular Therapy-Oncolytics
- Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
- (2020) Gil Awada et al. Journal for ImmunoTherapy of Cancer
- Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome
- (2020) María González‐Tablas et al. BRAIN PATHOLOGY
- Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma
- (2019) Junsik Park et al. CLINICAL CANCER RESEARCH
- Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients
- (2019) Denis Migliorini et al. NEURO-ONCOLOGY
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
- (2019) Niklas Schäfer et al. Journal of Translational Medicine
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
- (2019) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Brain Tumor Microenvironment and Host State: Implications for Immunotherapy
- (2019) William Tomaszewski et al. CLINICAL CANCER RESEARCH
- Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
- (2019) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment
- (2019) Adela Wu et al. JOURNAL OF NEURO-ONCOLOGY
- A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma
- (2019) Patrick Y. Wen et al. CLINICAL CANCER RESEARCH
- Mechanisms of immunotherapy resistance: lessons from glioblastoma
- (2019) Christopher M. Jackson et al. NATURE IMMUNOLOGY
- The Immunoscore: Colon Cancer and Beyond
- (2019) Helen K Angell et al. CLINICAL CANCER RESEARCH
- B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
- (2019) Dean Nehama et al. EBioMedicine
- A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
- (2019) Irene M. Ghobrial et al. CLINICAL CANCER RESEARCH
- RBTT-12. A PHASE I STUDY OF EGFRVIII-DIRECTED CAR T CELLS COMBINED WITH PD-1 INHIBITION IN PATIENTS WITH NEWLY, DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA: TRIAL IN PROGRESS
- (2019) Stephen Bagley et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
- (2019) Michael C. Burger et al. Frontiers in Immunology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
- (2018) Malte Mohme et al. CLINICAL CANCER RESEARCH
- T-cell Dysfunction in Glioblastoma: Applying a New Framework
- (2018) Karolina I. Woroniecka et al. CLINICAL CANCER RESEARCH
- T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
- (2018) Karolina Woroniecka et al. CLINICAL CANCER RESEARCH
- When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma
- (2018) Saskia Roesch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
- (2018) Linda M. Liau et al. Journal of Translational Medicine
- Current state of immunotherapy for glioblastoma
- (2018) Michael Lim et al. Nature Reviews Clinical Oncology
- A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial
- (2018) Marion Rapp et al. Trials
- Immune Microenvironment in Glioblastoma Subtypes
- (2018) Zhihong Chen et al. Frontiers in Immunology
- Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
- (2018) Carter M. Suryadevara et al. OncoImmunology
- A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
- (2018) Michael Platten et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.
- (2018) Manmeet Singh Ahluwalia et al. JOURNAL OF CLINICAL ONCOLOGY
- Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.
- (2018) John Frederick De Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
- (2018) Giulia Golinelli et al. CANCER GENE THERAPY
- Promising vaccines for treating glioblastoma
- (2018) Adam M. Swartz et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- The role of CMV in glioblastoma and implications for immunotherapeutic strategies
- (2018) Maryam Rahman et al. OncoImmunology
- Immune microenvironment of gliomas
- (2017) Anna Gieryng et al. LABORATORY INVESTIGATION
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- CD70, a novel target of CAR T-cell therapy for gliomas
- (2017) Linchun Jin et al. NEURO-ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- (2017) D. A. Reardon et al. NEURO-ONCOLOGY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Lack of cytomegalovirus detection in human glioma
- (2017) Araceli Garcia-Martinez et al. Virology Journal
- Tumor-infiltrating lymphocytes (TILs) from patients with glioma
- (2017) Zhenjiang Liu et al. OncoImmunology
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
- (2016) R. Rampling et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of microglia and macrophages in glioma maintenance and progression
- (2016) Dolores Hambardzumyan et al. NATURE NEUROSCIENCE
- HumanTERTpromoter mutation enables survival advantage fromMGMTpromoter methylation inIDH1wild-type primary glioblastoma treated by standard chemoradiotherapy
- (2016) HuyTram N. Nguyen et al. NEURO-ONCOLOGY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients
- (2016) Song Han et al. Oncology Letters
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- HER2 expression status in diverse cancers: review of results from 37,992 patients
- (2015) Min Yan et al. CANCER AND METASTASIS REVIEWS
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Prognostic role of tumour-infiltrating inflammatory cells in brain tumours
- (2015) Michał Bieńkowski et al. CURRENT OPINION IN NEUROLOGY
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- Discordant humoral and cellular immune responses toCytomegalovirus(CMV) in glioblastoma patients whose tumors are positive for CMV
- (2015) Afsar Rahbar et al. OncoImmunology
- IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
- (2015) Aymeric Amelot et al. PLoS One
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
- (2014) S Han et al. BRITISH JOURNAL OF CANCER
- The role of regulatory T-cells in glioma immunology
- (2014) Yinn Cher Ooi et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Beating the odds: extreme long-term survival with glioblastoma
- (2014) W. L. Bi et al. NEURO-ONCOLOGY
- Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
- (2014) C. Marcela Diaz-Montero et al. SEMINARS IN ONCOLOGY
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
- (2013) Einar Osland Vik-Mo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
- (2013) W. Wick et al. NEUROLOGY
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
- (2012) Valérie Dutoit et al. BRAIN
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- (2012) Surasak Phuphanich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
- (2012) C. A. Crane et al. CLINICAL CANCER RESEARCH
- Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-
- (2011) J. Lohr et al. CLINICAL CANCER RESEARCH
- The brain tumor microenvironment
- (2011) Nikki A. Charles et al. GLIA
- Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
- (2011) Stephanie E Combs et al. Radiation Oncology
- CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
- (2010) Isaac Yang et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- The EGFRvIII variant in glioblastoma multiforme
- (2009) Hui K. Gan et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
- (2008) Y Komohara et al. JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started